公开(公告)号：US12128095B2

公开(公告)日：2024-10-29

申请号：US17672126

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04 ,  C08B37/00

CPC classification number: A61K39/0258 ,  A61P31/04 ,  A61P37/04 ,  C08B37/006 ,  A61K2039/6037 ,  A61K2039/627

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US20230000966A1

公开(公告)日：2023-01-05

申请号：US17772610

申请日：2020-10-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Ye Che ,  Wei Chen ,  Laurent Oliver Chorro ,  Ling Chu ,  Robert G.K. Donald ,  Matthew Curtis Griffor ,  Jianxin Gu ,  Zeqiang Guan ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Scott Ellis Lomberk ,  Jason Arnold Lotvin ,  Nishith Merchant ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  David Robert Stead ,  Karen Kiyoko Takane

IPC: A61K39/108 ,  C07K14/245

Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.

公开(公告)号：US20220387613A1

公开(公告)日：2022-12-08

申请号：US17824293

申请日：2022-05-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Caitlyn Gallagher ,  Jianxin Gu ,  Isis Kanevsky ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Naveen Surendran

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04

Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.

公开(公告)号：US11260119B2

公开(公告)日：2022-03-01

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P31/04 ,  A61P37/04 ,  A61K39/00

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US10982198B2

公开(公告)日：2021-04-20

申请号：US16104938

申请日：2018-08-19

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C07K14/33 ,  C12N1/20 ,  C12N9/10

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10787652B2

公开(公告)日：2020-09-29

申请号：US14436875

申请日：2013-10-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10196429B2

公开(公告)日：2019-02-05

申请号：US15630147

申请日：2017-06-22

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen

IPC: A61K39/095 ,  C07K14/22

Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

公开(公告)号：US20180371030A1

公开(公告)日：2018-12-27

申请号：US15630147

申请日：2017-06-22

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen

IPC: C07K14/22 ,  A61K39/095

Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal

公开(公告)号：US09724402B2

公开(公告)日：2017-08-08

申请号：US15237005

申请日：2016-08-15

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

公开(公告)号：US20250002875A1

公开(公告)日：2025-01-02

申请号：US18593348

申请日：2024-03-01

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.